SLVNF (Solvonis Therapeutics) Net Income (Continuing Operations): $-7.71 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Solvonis Therapeutics Net Income (Continuing Operations)?

Solvonis Therapeutics SLVNF -58.33% Net Income (Continuing Operations) is $-7.71 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Solvonis Therapeutics's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was $-5.51 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.71 Mil.

Solvonis Therapeutics  (OTCPK:SLVNF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Solvonis Therapeutics Net Income (Continuing Operations) Related Terms

Solvonis Therapeutics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics Net Income (Continuing Operations) Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -0.64 -3.30 -3.95 -1.83 -7.68

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -0.60 -1.24 -2.20 -5.51

Solvonis Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-7.71 Mil mean?
Solvonis Therapeutics (SLVNF) has a Net Income (Continuing Operations) of $-7.71 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Solvonis Therapeutics and its competitors.
Is Solvonis Therapeutics' Net Income (Continuing Operations) too high?
Solvonis Therapeutics' current Net Income (Continuing Operations) is $-7.71 Mil.
How does Solvonis Therapeutics' Net Income (Continuing Operations) compare to ?
Solvonis Therapeutics' Net Income (Continuing Operations) of $-7.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Solvonis Therapeutics and its competitors. Solvonis Therapeutics's current Net Income (Continuing Operations) is $-7.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Solvonis Therapeutics (SLVNF) has a current Net Income (Continuing Operations) of $-7.71 Mil. The current Net Income (Continuing Operations) is $-7.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Solvonis Therapeutics (SLVNF), the current Net Income (Continuing Operations) is $-7.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Comparable Companies
Other Exchanges SVNS:UKJ4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.